Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease

Li Wang, Helmut Friess, Zhaowen Zhu, Hans Graber, Arthur Zimmermann, Murray Korc, Jean Claude Reubi, Markus W. Büchler

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

By autoradiography, neurotensin (NT) binding is specifically detectable in pancreatic cancer, but not in the normal pancreas, chronic pancreatitis (CP), or other pancreatic disorders. In the present study, we investigated whether this is due to NT receptor-1 (NTR-1) mRNA up-regulation and whether NTR-1 mRNA could also be used as a specific diagnostic marker and treatment target in pancreatic cancer. Fifteen normal pancreas tissue samples, 20 CP samples, and 30 pancreatic cancer samples were studied. Expression and localization of NTR-1 mRNA was investigated by Northern blot analysis and in situ hybridization. Furthermore, consecutive tissue sections were analyzed for NTR-1 mRNA expression and NT binding. By Northern blot analysis, NTR-1 mRNA expression was 4.4-fold (P <0.01) and 3.0-fold (P <0.01) higher in pancreatic cancer and CP tissue samples, respectively, compared with normal controls. There was no difference in NTR-1 mRNA levels between CP and cancer samples (P > 0.05). In pancreatic cancer, the NTR-1 mRNA levels were higher in advanced tumor stage (stages III and IV) than early tumor stage (stages I and II; P <0.05), but no difference was found between well/moderately differentiated (grades 1 and 2) and poorly differentiated/undifferentiated cancers (grades 3 and 4; P > 0.05). By in situ hybridization, NTR-1 mRNA signals were weakly present in the cytoplasm of acinar and ductal cells of the normal pancreas. Moderate to intense NTR-1 mRNA signals were present in the cytoplasm of acinar cells dedifferentiating into tubular complexes and degenerating acinar cells of CP samples. In the cancer samples, NTR-1 mRNA was moderately to intensely expressed in the cytoplasm of cancer cells. When on consecutive tissue sections NTR-1 mRNA expression was compared with the presence of NTR-1, measured by receptor autoradiography, a correlation was found in carcinomas but not in CP samples, in which no receptors were detectable by autoradiography. The enhanced expression of NTR-1 mRNA in pancreatic cancer cells further suggests that neuroendocrine hormones might modulate pancreas cancer cell behavior. However, its relatively high levels in CP excludes NTR-1 mRNA as a specific parameter for pancreatic cancer and for the differentiation of pancreatic cancer from CP.

Original languageEnglish (US)
Pages (from-to)566-571
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number2
StatePublished - Feb 2000
Externally publishedYes

Fingerprint

Pancreatic Diseases
Pancreas
Pancreatic Neoplasms
Messenger RNA
Chronic Pancreatitis
Acinar Cells
Autoradiography
Neurotensin
Cytoplasm
Northern Blotting
In Situ Hybridization
methylarginyl-lysyl-prolyl-tryptophyl-tert-leucyl-leucyl-ethyl ester
neurotensin type 1 receptor
Neoplasms
Up-Regulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wang, L., Friess, H., Zhu, Z., Graber, H., Zimmermann, A., Korc, M., ... Büchler, M. W. (2000). Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clinical Cancer Research, 6(2), 566-571.

Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. / Wang, Li; Friess, Helmut; Zhu, Zhaowen; Graber, Hans; Zimmermann, Arthur; Korc, Murray; Reubi, Jean Claude; Büchler, Markus W.

In: Clinical Cancer Research, Vol. 6, No. 2, 02.2000, p. 566-571.

Research output: Contribution to journalArticle

Wang, L, Friess, H, Zhu, Z, Graber, H, Zimmermann, A, Korc, M, Reubi, JC & Büchler, MW 2000, 'Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease', Clinical Cancer Research, vol. 6, no. 2, pp. 566-571.
Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, Korc M et al. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clinical Cancer Research. 2000 Feb;6(2):566-571.
Wang, Li ; Friess, Helmut ; Zhu, Zhaowen ; Graber, Hans ; Zimmermann, Arthur ; Korc, Murray ; Reubi, Jean Claude ; Büchler, Markus W. / Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 2. pp. 566-571.
@article{4105cf7aaae84b79b287d4a8c40b1eff,
title = "Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease",
abstract = "By autoradiography, neurotensin (NT) binding is specifically detectable in pancreatic cancer, but not in the normal pancreas, chronic pancreatitis (CP), or other pancreatic disorders. In the present study, we investigated whether this is due to NT receptor-1 (NTR-1) mRNA up-regulation and whether NTR-1 mRNA could also be used as a specific diagnostic marker and treatment target in pancreatic cancer. Fifteen normal pancreas tissue samples, 20 CP samples, and 30 pancreatic cancer samples were studied. Expression and localization of NTR-1 mRNA was investigated by Northern blot analysis and in situ hybridization. Furthermore, consecutive tissue sections were analyzed for NTR-1 mRNA expression and NT binding. By Northern blot analysis, NTR-1 mRNA expression was 4.4-fold (P <0.01) and 3.0-fold (P <0.01) higher in pancreatic cancer and CP tissue samples, respectively, compared with normal controls. There was no difference in NTR-1 mRNA levels between CP and cancer samples (P > 0.05). In pancreatic cancer, the NTR-1 mRNA levels were higher in advanced tumor stage (stages III and IV) than early tumor stage (stages I and II; P <0.05), but no difference was found between well/moderately differentiated (grades 1 and 2) and poorly differentiated/undifferentiated cancers (grades 3 and 4; P > 0.05). By in situ hybridization, NTR-1 mRNA signals were weakly present in the cytoplasm of acinar and ductal cells of the normal pancreas. Moderate to intense NTR-1 mRNA signals were present in the cytoplasm of acinar cells dedifferentiating into tubular complexes and degenerating acinar cells of CP samples. In the cancer samples, NTR-1 mRNA was moderately to intensely expressed in the cytoplasm of cancer cells. When on consecutive tissue sections NTR-1 mRNA expression was compared with the presence of NTR-1, measured by receptor autoradiography, a correlation was found in carcinomas but not in CP samples, in which no receptors were detectable by autoradiography. The enhanced expression of NTR-1 mRNA in pancreatic cancer cells further suggests that neuroendocrine hormones might modulate pancreas cancer cell behavior. However, its relatively high levels in CP excludes NTR-1 mRNA as a specific parameter for pancreatic cancer and for the differentiation of pancreatic cancer from CP.",
author = "Li Wang and Helmut Friess and Zhaowen Zhu and Hans Graber and Arthur Zimmermann and Murray Korc and Reubi, {Jean Claude} and B{\"u}chler, {Markus W.}",
year = "2000",
month = "2",
language = "English (US)",
volume = "6",
pages = "566--571",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease

AU - Wang, Li

AU - Friess, Helmut

AU - Zhu, Zhaowen

AU - Graber, Hans

AU - Zimmermann, Arthur

AU - Korc, Murray

AU - Reubi, Jean Claude

AU - Büchler, Markus W.

PY - 2000/2

Y1 - 2000/2

N2 - By autoradiography, neurotensin (NT) binding is specifically detectable in pancreatic cancer, but not in the normal pancreas, chronic pancreatitis (CP), or other pancreatic disorders. In the present study, we investigated whether this is due to NT receptor-1 (NTR-1) mRNA up-regulation and whether NTR-1 mRNA could also be used as a specific diagnostic marker and treatment target in pancreatic cancer. Fifteen normal pancreas tissue samples, 20 CP samples, and 30 pancreatic cancer samples were studied. Expression and localization of NTR-1 mRNA was investigated by Northern blot analysis and in situ hybridization. Furthermore, consecutive tissue sections were analyzed for NTR-1 mRNA expression and NT binding. By Northern blot analysis, NTR-1 mRNA expression was 4.4-fold (P <0.01) and 3.0-fold (P <0.01) higher in pancreatic cancer and CP tissue samples, respectively, compared with normal controls. There was no difference in NTR-1 mRNA levels between CP and cancer samples (P > 0.05). In pancreatic cancer, the NTR-1 mRNA levels were higher in advanced tumor stage (stages III and IV) than early tumor stage (stages I and II; P <0.05), but no difference was found between well/moderately differentiated (grades 1 and 2) and poorly differentiated/undifferentiated cancers (grades 3 and 4; P > 0.05). By in situ hybridization, NTR-1 mRNA signals were weakly present in the cytoplasm of acinar and ductal cells of the normal pancreas. Moderate to intense NTR-1 mRNA signals were present in the cytoplasm of acinar cells dedifferentiating into tubular complexes and degenerating acinar cells of CP samples. In the cancer samples, NTR-1 mRNA was moderately to intensely expressed in the cytoplasm of cancer cells. When on consecutive tissue sections NTR-1 mRNA expression was compared with the presence of NTR-1, measured by receptor autoradiography, a correlation was found in carcinomas but not in CP samples, in which no receptors were detectable by autoradiography. The enhanced expression of NTR-1 mRNA in pancreatic cancer cells further suggests that neuroendocrine hormones might modulate pancreas cancer cell behavior. However, its relatively high levels in CP excludes NTR-1 mRNA as a specific parameter for pancreatic cancer and for the differentiation of pancreatic cancer from CP.

AB - By autoradiography, neurotensin (NT) binding is specifically detectable in pancreatic cancer, but not in the normal pancreas, chronic pancreatitis (CP), or other pancreatic disorders. In the present study, we investigated whether this is due to NT receptor-1 (NTR-1) mRNA up-regulation and whether NTR-1 mRNA could also be used as a specific diagnostic marker and treatment target in pancreatic cancer. Fifteen normal pancreas tissue samples, 20 CP samples, and 30 pancreatic cancer samples were studied. Expression and localization of NTR-1 mRNA was investigated by Northern blot analysis and in situ hybridization. Furthermore, consecutive tissue sections were analyzed for NTR-1 mRNA expression and NT binding. By Northern blot analysis, NTR-1 mRNA expression was 4.4-fold (P <0.01) and 3.0-fold (P <0.01) higher in pancreatic cancer and CP tissue samples, respectively, compared with normal controls. There was no difference in NTR-1 mRNA levels between CP and cancer samples (P > 0.05). In pancreatic cancer, the NTR-1 mRNA levels were higher in advanced tumor stage (stages III and IV) than early tumor stage (stages I and II; P <0.05), but no difference was found between well/moderately differentiated (grades 1 and 2) and poorly differentiated/undifferentiated cancers (grades 3 and 4; P > 0.05). By in situ hybridization, NTR-1 mRNA signals were weakly present in the cytoplasm of acinar and ductal cells of the normal pancreas. Moderate to intense NTR-1 mRNA signals were present in the cytoplasm of acinar cells dedifferentiating into tubular complexes and degenerating acinar cells of CP samples. In the cancer samples, NTR-1 mRNA was moderately to intensely expressed in the cytoplasm of cancer cells. When on consecutive tissue sections NTR-1 mRNA expression was compared with the presence of NTR-1, measured by receptor autoradiography, a correlation was found in carcinomas but not in CP samples, in which no receptors were detectable by autoradiography. The enhanced expression of NTR-1 mRNA in pancreatic cancer cells further suggests that neuroendocrine hormones might modulate pancreas cancer cell behavior. However, its relatively high levels in CP excludes NTR-1 mRNA as a specific parameter for pancreatic cancer and for the differentiation of pancreatic cancer from CP.

UR - http://www.scopus.com/inward/record.url?scp=0033956470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033956470&partnerID=8YFLogxK

M3 - Article

C2 - 10690540

AN - SCOPUS:0033956470

VL - 6

SP - 566

EP - 571

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -